Steve Scala
Stock Analyst at TD Cowen
(4.49)
# 1,037
Out of 4,402 analysts
388
Total ratings
62.8%
Success rate
10.2%
Average return
Main Sectors:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GSK GSK plc | Maintained: Hold | $70 | $52.86 | +32.43% | 29 | Jun 11, 2026 | |
| NVS Novartis AG | Maintained: Hold | $148 → $180 | $153.92 | +16.94% | 34 | Jun 11, 2026 | |
| ZTS Zoetis | Maintained: Buy | $150 | $81.40 | +84.28% | 23 | May 7, 2026 | |
| NVAX Novavax | Rated: Hold | $8 → $9 | $9.03 | -0.33% | 5 | May 6, 2026 | |
| PFE Pfizer | Maintained: Hold | $30 | $26.17 | +14.64% | 43 | May 6, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | n/a | $13,578.00 | - | 8 | Apr 30, 2026 | |
| SNY Sanofi | Rated: Hold | $57 | $44.11 | +29.22% | 24 | Apr 23, 2026 | |
| RHHBY Roche Holding AG | Maintained: Hold | $67 | $51.35 | +30.48% | 27 | Apr 23, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,250 | $1,160.95 | +7.67% | 47 | Apr 2, 2026 | |
| MRK Merck & Co. | Maintained: Hold | $120 → $137 | $120.76 | +13.45% | 31 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $280 | $224.77 | +24.57% | 39 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $24.05 | -0.21% | 16 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $64 → $54 | $56.90 | -5.10% | 29 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $19 → $15 | $13.45 | n/a | 4 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16.72 | $7.20 | n/a | 2 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $42 | $55.29 | n/a | 4 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.70 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.45 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 96.59 → CHF 109.47 | $121.54 | n/a | 3 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 → $155 | $43.96 | n/a | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 1,054 | $280.53 | n/a | 1 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 2,250p → 1,790p | $1,962.50 | n/a | 2 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | CHF 367.00 | $325.30 | n/a | 3 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | €41.55 → €98.00 | $76.30 | n/a | 2 | Jul 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.29 | n/a | 1 | Jun 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €67.51 → €74.44 | $135.40 | n/a | 4 | Dec 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $209 | $354.06 | n/a | 2 | Oct 3, 2017 |
GSK plc
Jun 11, 2026
Maintained: Hold
Price Target: $70
Current: $52.86
Upside: +32.43%
Novartis AG
Jun 11, 2026
Maintained: Hold
Price Target: $148 → $180
Current: $153.92
Upside: +16.94%
Zoetis
May 7, 2026
Maintained: Buy
Price Target: $150
Current: $81.40
Upside: +84.28%
Novavax
May 6, 2026
Rated: Hold
Price Target: $8 → $9
Current: $9.03
Upside: -0.33%
Pfizer
May 6, 2026
Maintained: Hold
Price Target: $30
Current: $26.17
Upside: +14.64%
AstraZeneca PLC
Apr 30, 2026
Maintained: Buy
Price Target: n/a
Current: $13,578.00
Upside: -
Sanofi
Apr 23, 2026
Rated: Hold
Price Target: $57
Current: $44.11
Upside: +29.22%
Roche Holding AG
Apr 23, 2026
Maintained: Hold
Price Target: $67
Current: $51.35
Upside: +30.48%
Eli Lilly and Company
Apr 2, 2026
Maintained: Buy
Price Target: $1,250
Current: $1,160.95
Upside: +7.67%
Merck & Co.
Mar 30, 2026
Maintained: Hold
Price Target: $120 → $137
Current: $120.76
Upside: +13.45%
Feb 4, 2026
Maintained: Buy
Price Target: $280
Current: $224.77
Upside: +24.57%
Dec 10, 2025
Reiterated: Buy
Price Target: $24
Current: $24.05
Upside: -0.21%
Jul 31, 2025
Maintained: Hold
Price Target: $64 → $54
Current: $56.90
Upside: -5.10%
Apr 22, 2025
Maintained: Hold
Price Target: $19 → $15
Current: $13.45
Upside: n/a
Feb 21, 2025
Maintained: Hold
Price Target: $16.72
Current: $7.20
Upside: n/a
Dec 24, 2024
Rated: Buy
Price Target: $42
Current: $55.29
Upside: n/a
Nov 18, 2024
Downgraded: Hold
Price Target: n/a
Current: $2.70
Upside: n/a
Nov 18, 2024
Downgraded: Hold
Price Target: n/a
Current: $4.45
Upside: n/a
Nov 11, 2024
Maintained: Hold
Price Target: CHF 96.59 → CHF 109.47
Current: $121.54
Upside: n/a
Apr 30, 2024
Reiterated: Buy
Price Target: $80 → $155
Current: $43.96
Upside: n/a
Mar 11, 2024
Maintained: Buy
Price Target: kr 1,054
Current: $280.53
Upside: n/a
Nov 30, 2023
Maintained: Hold
Price Target: 2,250p → 1,790p
Current: $1,962.50
Upside: n/a
Nov 14, 2022
Downgraded: Hold
Price Target: CHF 367.00
Current: $325.30
Upside: n/a
Jul 21, 2021
Initiated Coverage: Hold
Price Target: €41.55 → €98.00
Current: $76.30
Upside: n/a
Jun 24, 2021
Maintained: Buy
Price Target: n/a
Current: $4.29
Upside: n/a
Dec 10, 2018
Reiterated: Hold
Price Target: €67.51 → €74.44
Current: $135.40
Upside: n/a
Oct 3, 2017
Reiterated: Buy
Price Target: $209
Current: $354.06
Upside: n/a